Indian Biotech Startups Develop Innovative, Affordable Therapies for Vitiligo and Kidney Diseases
Two Indian biotech startups are advancing innovative therapies targeting challenging medical conditions. Pune-based Ahammune Biosciences is developing AB1001, a drug for vitiligo that aims to prevent disease progression and restore pigmentation, now in phase 2 trials with modest funding. Hyderabad-based Helex Inc is working on gene-editing medicines to safely target kidney cells, focusing on affordability and accessibility for Indian patients. Both companies emphasize cost-effective innovation to address unmet medical needs in India.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 41/100.
Outlets measured: mint, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 28 Oct, 12:32 am. Other outlets followed.
- 1